Yoko Fuyuno
Fukuoka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Tapinarof as a Therapeutic Aryl Hydrocarbon Receptor-Modulating Agent in the Treatment of Atopic Dermatitis.
Journal: The Journal of dermatology
Published: February 20, 2026
Cutaneous Adverse Events Following COVID-19 Vaccination in Japan: A Questionnaire Survey.
Journal: Cureus
Published: March 08, 2025
Successful control of recurrent MAS by canakinumab in a Sjögren syndrome patient with homozygous MEFV P369S variants and review of literatures.
Journal: Modern rheumatology case reports
Published: December 24, 2024
Therapeutic Agents with AHR Inhibiting and NRF2 Activating Activity for Managing Chloracne.
Journal: Antioxidants (Basel, Switzerland)
Published: June 13, 2018
Corrigendum to "Perillaldehyde Inhibits AHR Signaling and Activates NRF2 Antioxidant Pathway in Human Keratinocytes".
Journal: Oxidative medicine and cellular longevity
Published: March 25, 2018
Perillaldehyde Inhibits AHR Signaling and Activates NRF2 Antioxidant Pathway in Human Keratinocytes.
Perillaldehyde Inhibits AHR Signaling and Activates NRF2 Antioxidant Pathway in Human Keratinocytes.
Journal: Oxidative medicine and cellular longevity
Published: October 26, 2017
6-Formylindolo[3,2-b]Carbazole Accelerates Skin Wound Healing via Activation of ERK, but Not Aryl Hydrocarbon Receptor.
Journal: The Journal of investigative dermatology
Published: April 13, 2016
Verruciform xanthoma developing in eroded skin of recessive dystrophic epidermolysis bullosa.
Journal: European journal of dermatology : EJD
Published: August 06, 2015
Upregulation of S100P, receptor for advanced glycation end products and ezrin in malignant melanoma.
Upregulation of S100P, receptor for advanced glycation end products and ezrin in malignant melanoma.
Journal: The Journal of dermatology
Published: August 22, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026